➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
Colorcon
Express Scripts
Moodys

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Enalapril maleate; hydrochlorothiazide - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for enalapril maleate; hydrochlorothiazide and what is the scope of patent protection?

Enalapril maleate; hydrochlorothiazide is the generic ingredient in two branded drugs marketed by Cosette, Dr Reddys Labs Ltd, Ivax Sub Teva Pharms, Mylan, Nostrum Labs Inc, Taro Pharm Inds, Upsher Smith Labs, and Bausch, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for enalapril maleate; hydrochlorothiazide. Six suppliers are listed for this compound.

Summary for enalapril maleate; hydrochlorothiazide
Pharmacology for enalapril maleate; hydrochlorothiazide

US Patents and Regulatory Information for enalapril maleate; hydrochlorothiazide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE enalapril maleate; hydrochlorothiazide TABLET;ORAL 075788-002 Sep 18, 2001 AB RX No No   Start Trial   Start Trial   Start Trial
Bausch VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-003 Jul 12, 1995 AB RX Yes No   Start Trial   Start Trial   Start Trial
Nostrum Labs Inc ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE enalapril maleate; hydrochlorothiazide TABLET;ORAL 076486-002 Oct 27, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
Ivax Sub Teva Pharms ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE enalapril maleate; hydrochlorothiazide TABLET;ORAL 075736-002 Mar 25, 2003 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for enalapril maleate; hydrochlorothiazide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-003 Jul 12, 1995   Start Trial   Start Trial
Bausch VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-001 Oct 31, 1986   Start Trial   Start Trial
Bausch VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-001 Oct 31, 1986   Start Trial   Start Trial
Bausch VASERETIC enalapril maleate; hydrochlorothiazide TABLET;ORAL 019221-003 Jul 12, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Moodys
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.